azomycin has been researched along with Cross Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nambiar, S; Schumann, K; Walinsky, S | 1 |
| Chalkley, LJ; Janse Van Rensburg, MN; Theron, MM | 1 |
2 other study(ies) available for azomycin and Cross Infection
| Article | Year |
|---|---|
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration | 2021 |
Nitroimidazole resistance genes (nimB) in anaerobic Gram-positive cocci (previously Peptostreptococcus spp.).
Topics: Bacterial Proteins; Cross Infection; Drug Resistance, Bacterial; Drug Resistance, Microbial; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Nitroimidazoles; Peptostreptococcus; Reverse Transcriptase Polymerase Chain Reaction; South Africa | 2004 |